A phase 1 clinical trial of SiS-101-ADO2
Latest Information Update: 18 May 2023
At a glance
- Drugs SIS 101 ADO (Primary)
- Indications Osteoporosis
- Focus Adverse reactions; First in man
Most Recent Events
- 15 May 2023 According to a SiSaf media release, the company is working with CSSi LifeSciences, a leader in shepherding emerging therapeutics through federal approval processes, to co-ordinate the complex regulatory process that is required for the clinical trials of SIS-101-ADO.
- 12 Sep 2022 According to a SiSaf media release, company plans IND submission to the U.S. FDA within the next six months.
- 16 Nov 2021 New trial record